Biotech Hangout cover image

Episode 78

Biotech Hangout

00:00

BMS-LEON Bio deal and Novartis' phase three trial update on plu victo

This chapter discusses a $350 million deal between BMS and LEON Bio, as well as Novartis' disappointing update on their phase three trial of plu victo. The speaker highlights the impact of drug pricing in China on both companies.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app